US 7,691,401 B2Grant

Poly(butylmethacrylate) and rapamycin coated stent

Issue Date:2010-04-06

•18 Claims

•4 Drawing Sheets

Abstract

An implantable medical device, such as a stent, is disclosed. The device includes a substrate and a polymeric layer including poly(methylmethacrylate) or poly(butylmethacrylate) supported by the substrate. The polymeric layer contains rapamycin. A barrier is over at least a portion of the polymeric layer to reduce the rate of release of rapamycin from the implantable medical device. The polymeric layer can additionally include poly(ethylene co-vinyl acetate).

Metadata

Assignee

Advanced Cardiovascular Systems, Inc.

Inventors

Daniel Castro
Stephen D. Pacetti

Application Information

Application Number:US 11/132,048

Filing Date:2005-05-17

Priority Date:2000-09-28

Art Unit:1615

Classifications

IPC:

A61F2/04

Patent Drawings (4 sheets)

Description

CROSS REFERENCE

[0001] This is a divisional application of U.S. patent application Ser. No. 10/678,346 filed Oct. 3, 2003, now U.S. Pat. No. 6,953,560 which is a continuation of U.S. patent application Ser. No. 09/676,049 filed Sep. 28, 2000 now U.S. Pat. No. 6,716,444. This divisional application claims the priority benefit of U.S. patent application Ser. No. 10/678,346, filed Oct. 3, 2000, now abandoned, and U.S. patent application Ser. No. 09/676,049 filed Sep. 22, 2000, now U.S. Pat. No. 6,716,444, and this divisional application hereby incorporates by reference the complete contents of these applications.

BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] The present invention relates to implantable medical devices that release a drug.

[0004] 2. Description of the Background

[0005] Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the arterial lumen. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.

[0006] In treating the damaged vasculature tissue, and to deter thrombosis and restenosis, drugs are commonly administered to the treatment site. For example, anticoagulants are commonly used to prevent thrombosis of the coronary lumen. Antiplatelets are administered to reduce the incidence of major adverse cardiac events. Cytostatic agents are presently used in clinical trials to reduce post-angioplasty proliferation of the vascular tissue.

[0007] Systemic administration of such drugs in sufficient amounts to supply an efficacious concentration to the local treatment site often produces adverse or toxic side effects for the patient. Accordingly, local delivery is a preferred method of treatment since smaller amounts of medication are administered in comparison to systemic dosages, but the medication is concentrated at a specific treatment site. Local delivery thus produces fewer side effects and achieves more effective results.

[0008] A common technique for local delivery of drugs involves coating a stent or graft with a polymeric material which, in turn, is impregnated with a drug or a combination of drugs. Once the stent or graft is implanted within a cardiovascular system lumen, the drug(s) is released from the polymer for the treatment of the local tissues. U.S. Pat. No. 5,605,696 to Eury et al., U.S. Pat. No. 5,464,650 to Berg, et al., and U.S. Pat. No. 5,700,286 to Tartaglia, et al. provide examples illustrating the use of a polymeric coating for the local delivery of a drug or substance.

[0009] Stents are scaffoldings, usually cylindrical or tubular in shape, which are inserted into an anatomical passageway and operate to physically hold open and, if desired, to expand the wall of a passageway. Stents are capable of being crimped onto balloon catheters for insertion through small cavities, positioned in a desired location, and then expanded to a larger diameter. Stents can be either balloon expandable or self-expanding.

[0010] Grafts are typically placed in a blood vessel to either replace a diseased segment that has been removed, or to form a bypass conduit through a damaged segment of the vessel wall as is the case with an aneurysm, for example. The graft has a tubular portion which spans the site of the damaged tissue and through which the blood flows. The graft has sections at both ends of the tube that are used to secure the graft to the inside of a vessel wall. The graft also has an outer surface, portions of which are in contact with an inner surface of the blood vessel wall, and an inner surface in contact with the blood flowing through the vessel.

[0011] FIG. 1 shows an implantable medical device 10, which may be a stent or graft. Device 10 includes a substrate 12 that may be formed of stainless steel, nickel titanium alloy, or another biocompatible metal. Substrate 12 is covered (usually conformally) by a first layer 14. First layer 14 includes polymer containing a drug 16.

[0012] An equation describing the drug release rate per unit area of device 10 is as follows:

[0013]

\begin{matrix} \begin{matrix} Φ (t) = D_{p} \sum_{n = 0}^{\infty} b_{n} \exp (\frac{- π^{2} D_{p} {t (2 n + 1)}^{2}}{4 T^{2}}) \\ (\frac{- π}{2 {T (2 n + 1)}^{n}}) \end{matrix} & (Equation 1) \end{matrix}

where Φ(t)=release rate of drug as a function of time,

[0014] D_p=diffusivity of drug 16 in polymer film 14,

[0015] π=3.14159,

[0016] T=thickness of polymer film 14,

[0017]

and b_{n} = \frac{2}{T} \int_{o}^{T} C_{o} \cos {\frac{π x (2 n + 1)}{2 T}} ⅆ x

[0018] where C_ois the concentration of drug in the polymer at time zero.

[0019] Equation 1 assumes that: (1) all resistance to drug release is determined by the diffusivity of drug 16 in polymer 14; (2) the concentration of drug 16 is uniform throughout; (3) drug 16 does not go into the metallic surface 12; and (4) drug 16 is rapidly removed from the surface of polymer 14 as soon as drug 16 is released from polymer 14.

[0020] The diffusivity of drug 16 in polymer 14, D_p, in turn is determined by certain properties of drug 16 (e.g., molecular weight, size) and physical properties of the polymer 14 through which drug 16 is diffusing (e.g., pore size, crystallinity, glass transition temperature, polarity or hydrophobicity).

[0021] FIG. 2 illustrates the predicted drug release rate curve for a polymer matrix carrying a drug, such as first layer 14, illustrated in FIG. 1. Curve 8 is an exponentially decreasing curve.

[0022] A problem associated with the use of a polymeric coating as a matrix for carrying the drug is that the rate at which the drug is released is highly variable, typically exhibiting a very high rate of release after the medical device is implanted in the patient, followed by a significantly lower rate of release. This may be undesirable in many applications, since the initial concentrations may be too high (causing undesirable side effects or even cell death), the later concentrations may be too low to have any therapeutic effect, and the overall residence time of the drug in the target area may be too short to provide the desired therapeutic effect.

[0023] For example, for certain antiproliferative drugs, a residence time of thirty minutes may be all that is required to achieve a permanent effect, while others may take up to two weeks. Where nitrous oxide (NO) is used as the antiproliferative drug, a residence time of four to eight weeks is desirable, but even longer durations up to twelve weeks may be beneficial, depending on the patient.

[0024] With respect to anti-inflammatory drugs, a long residence time (e.g., several weeks) is desirable, because the anti-inflammatory drug should be delivered until some amount of healing has occurred. Anti-thrombogenic drugs also may require a long residence time, for example, up to five months, since that much time may be required for a stent to become endothelialized.

[0025] Thus, there is a need for a mechanism for controlling the release rate of drugs from implantable medical devices to increase the efficacy of local drug delivery in treating patients.

SUMMARY OF THE INVENTION

[0026] The present invention allows for a controlled rate of release of a drug or drugs from a polymer carried on an implantable medical device. The controlled rate of release allows localized drug delivery for extended periods, e.g., weeks to months, depending upon the application. This is especially useful in providing therapy to reduce or prevent cell proliferation, inflammation, or thrombosis in a localized area.

[0027] One embodiment of an implantable medical device in accordance with the present invention includes a substrate, which may be, for example, a metal or polymeric stent or graft, among other possibilities. At least a portion of the substrate is coated with a first layer that includes one or more drugs in a polymer carrier. A barrier coating overlies the first layer. The barrier (which may be considered a coating) reduces the rate of release of the drug from the polymer once the medical device has been placed into the patient's body, thereby allowing an extended period of localized drug delivery once the medical device is in situ.

[0028] The barrier is necessarily biocompatible (i.e., its presence does not elicit an adverse response from the body), and typically has a thickness ranging from about 50 angstroms to about 20,000 angstroms. It is contemplated that the barrier contains mostly inorganic material. However, some organic compounds (e.g., polyacrylonitrile, polyvinylidene chloride, nylon 6-6, perfluoropolymers, polyethylene terephthalate, polyethylene 2,6-napthalene dicarboxylate, and polycarbonate) may be incorporated in the barrier. Suitable inorganic materials for use within the barrier include, but are not limited to, inorganic elements, such as pure metals including aluminum, chromium, gold, hafnium, iridium, niobium, palladium, platinum, tantalum, titanium, tungsten, zirconium, and alloys of these metals, and inorganic compounds, such as inorganic silicides, oxides, nitrides, and carbides. Generally, the solubility of the drug in the material of the barrier is significantly less than the solubility of the drug in the polymer carrier. Also, generally, the diffusivity of the drug in the material of the barrier is significantly lower than the diffusivity of the drug in the polymer carrier.

[0029] The barrier may or may not be biodegradable (i.e., capable of being broken down into harmless compounds by the action of the body). While it is contemplated that non-biodegradable barrier may be preferable, some biodegradable materials may be used as barriers. For example, calcium phosphates such as hydroxyapatite, carbonated hydroxyapatite, tricalcium phosphate, beta-tricalcium phosphate, octacalcium phosphate, amorphous calcium phosphate, and calcium orthophosphate may be used. Certain calcium salts such as calcium phosphate (plaster of paris) may also be used. The biodegradability of the barrier may act as an additional mechanism for controlling drug release from the underlying first layer.

[0030] The one or more drugs contained within the polymer may include, but are not limited to, antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, fibrinolytic, thrombin inhibitor, antimitotic, antiallergic, and antiproliferative substances.

[0031] In accordance with one embodiment of the present invention, the barrier is a homogeneous layer. A homogeneous layer of barrier may be produced by several methods, depending on the type of materials selected from the barrier. For example, nitride barriers, such as titanium nitride and chromium nitride, may be deposited by cathodic arc physical vapor deposition. Oxide barriers, such as silicon dioxide and aluminum oxide, can be produced by reactive sputtering. Metallic barriers, such as aluminum, gold, tungsten, platinum, or alloys of metals, may be produced by sputtering, thermal evaporation, or electron beam evaporation, as well as electroless deposition.

[0032] In accordance with another embodiment of the present invention, the barrier is formed by a number of discrete deposits on the surface of the polymer coating. The release rate of the drug from the polymer coating may be manipulated by controlling the fraction of the surface area covered by the barrier. Such a barrier may be obtained, for example, by cathodic arc sputtering, reactive sputtering, thermal evaporation, and electron beam (e-beam) evaporation of materials such as aluminum, chromium, gold, iridium, niobium, platinum, tantalum, titanium, and tungsten.

[0033] In accordance with another embodiment of the present invention, the barrier is intermixed with the first layer at and near the outer surface of the first layer, rather than being a discrete layer atop the first layer. This embodiment may be produced by several techniques, including for example, ion implantation, plasma ion implantation, alkoxide hydrolysis, and electroless deposition. Ion implantation and plasma ion implantation may produce, for example, titanium and palladium barrier coatings. Alkoxide hydrolysis may produce barrier coatings of titanium oxide, zirconium oxide, and aluminum oxide from titanium alkoxides, zirconium alkoxides and aluminum alkoxides, respectively. Electroless deposition may produce, for example, palladium and gold barrier coatings.

[0034] These and other embodiments and aspects of the present invention may be better understood in view of the drawings and the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0035] FIG. 1 is a partial cross-sectional view of a conventional implantable medical device having a polymer coating that carries a drug.

[0036] FIG. 2 illustrates a theoretical drug release rate curve for the implantable medical device of FIG. 1.

[0037] FIG. 3 is a partial cross-sectional view of a barrier on the surface of a polymer-coated implantable medical device in accordance with one embodiment of the present invention.

[0038] FIG. 4 is a partial cross-sectional view of a barrier on the surface of a polymer-coated implantable medical device in accordance with a second embodiment of the present invention.

[0039] FIG. 5 is a graph depicting the release of dexamethasone acetate from a silicone polymer and the predicted release of dexamethasone acetate when a barrier is applied to the silicone polymer.

[0040] FIG. 6 is a partial cross-sectional view of various types of barriers on or near the surface of an implantable medical device in accordance with a third embodiment of the present invention.

[0041] The use of the same reference numbers in different drawings indicates similar or identical items.

DETAILED DESCRIPTION

[0042] FIG. 3 is a partial cross-sectional view of implantable medical device 11, which may be a stent or graft, among other possibilities. Medical device 11 includes a substrate 12. A first layer 24 is present on the outer surface of substrate 12. First layer 24 includes a polymer and one or more drugs 16 carried within the polymer. First layer 24 can have a thickness ranging from about 2,000 angstroms to about 200,000 angstroms, or more particularly from about 10,000 angstroms to about 100,000 angstroms. Barrier 28 is present as a homogenous layer on the top surface of first layer 24. Barrier 28 is biocompatible, and typically has a thickness ranging from about 50 angstroms to about 20,000 angstroms, e.g., from about 100 angstroms to about 5,000 angstroms. In this embodiment, barrier 28 is an inorganic material.

[0043] Barrier 28 acts to reduce the rate of delivery of drug 16 to internal target tissue area 50 by at least one of two mechanisms. First, the solubility of drug 16 in barrier 28 is substantially less (i.e., at least two to three orders of magnitude less) than the solubility of drug 16 in first layer 24. Likewise, the diffusivity of drug 16 in barrier 28 is significantly lower than the diffusivity of drug 16 in first layer 24. Accordingly, drug 16 will diffuse more slowly through barrier 28 than through first layer 24. Secondly, barrier 28, being mostly an inorganic material, is composed of much smaller molecules than those found within the polymer in first layer 24. The barrier molecules are aligned more tightly and in a more orderly fashion than the polymer molecules, thereby leaving less void space through which drug 16 can travel.

[0044] Some barriers, especially defect-free metallic films and SiO_xfilms, will be very impermeable, except for microfractures through the barrier coating. While these microfractures may link the top and bottom of the barrier coating, the paths of the microfractures linking the top and bottom of the barrier coating are tortuous, and thus the path that drug 16 must take to exit medical device 11 is much longer than the thickness of barrier 28. Moreover, since the drug is restricted to diffusing only through the microfractures, the area available for diffusion is greatly reduced as well.

[0045] A simple model for the embodiment illustrated in FIG. 3 holds that the rate of release of drug 16 from barrier 28 per unit area may be expressed by the following equation:

[0046]

\begin{matrix} Release  rate = \frac{D_{I} k}{T_{I}} C_{p}^{o} \exp {\frac{- D_{I} kt}{T_{p} T_{I}}} & (Equation 2) \end{matrix}

[0047] where D_I=diffusivity of drug 16 in barrier 28;

- [0048] k=partition coefficient for drug 16 between first layer 24 and barrier 28;
- [0049] T_I=thickness of barrier 28;
- [0050] C_p^o=initial concentration of drug 16 in barrier 28; and
- [0051] T_P=thickness of first layer 24.
  This equation assumes that all of the resistance to drug release is in the barrier 28. This is a reasonable assumption since, typically, D_Iis at least two to three orders of magnitude lower than the diffusivity of drug 16 in first layer 24. As can be seen from Equation 2, variables D_I, k, and T_I, are the most significant variables affecting drug release. Of course, the present invention does not depend on this equation or the assumptions discussed above.

[0052] Suitable inorganic materials for barrier 28 include, but are not limited to, silicides, oxides, nitrides, and carbides. Suitable silicides may include silicides of vanadium, zirconium, tungsten, titanium, niobium, and tantalum. Suitable oxides may include oxides of aluminum, barium, calcium, hafnium, niobium, silicon, tantalum, titanium, tungsten, and zirconium. Suitable nitrides may include nitrides of chromium, silicon, titanium, and zirconium. Suitable carbides may include carbides of silicon and titanium. Other suitable materials may include molybdenum disulfide, amorphous diamond, diamond-like carbon, pyrolytic carbon, ultra-low temperature isotropic (ULTI) carbon, amorphous carbon, strontium titanate, and barium titanate. Also suitable for use are pure metals, such as aluminum, chromium, gold, hafnium, iridium, niobium, palladium, platinum, tantalum, titanium, tungsten, zirconium, and alloys of these metals.

[0053] Several methods may be used to deposit barrier 28 on first layer 24, depending on the application. For example, silicide compounds, such as vanadium disilicide, zirconium disilicide, tungsten disilicide, titanium disilicide, niobium disilicide, tantalum disilicide, vanadium silicide, titanium trisilicide, and tantalum trisilicide may be deposited by sputtering or chemical vapor deposition (CVD).

[0054] Oxide barrier coatings, such as tantalum oxide, titanium dioxide, zirconium oxide, niobium oxide, tungsten oxide, aluminum oxide, and silicon dioxide can be produced by reactive sputtering. The power source used in this method may be AC or DC, and utilizes the pure element as a target with a sputter gas of argon and low levels of oxygen.

[0055] Nitride barrier coatings, such as titanium nitride, titanium carbo nitride, chromium nitride, titanium aluminum nitride, and zirconium nitride can be deposited on first layer 24 at relatively low temperatures (i.e., less than 60° C.) by cathodic arc vacuum deposition. Such a method may be chosen where first layer 24 and drug 16 are temperature-sensitive.

[0056] Films of pure metals (e.g., aluminum, gold, tungsten, platinum) may be produced by physical vapor deposition (PVD) methods such as sputtering, thermal evaporation, or electron beam evaporation. Alloys of these metals can be deposited by sputtering if, for example, an alloy sputtering target is used or multiple metal targets are simultaneously sputtered. Alloys may also be deposited utilizing thermal evaporation or electron beam evaporation if several evaporation sources are used simultaneously.

[0057] Suitable polymer materials for first layer 24 can include, but are not limited to, polyurethanes, polyesterurethanes, silicone, fluoropolymers, ethylene vinyl acetate, polyethylene, polypropylene, polycarbonates, trimethylenecarbonate, polyphosphazene, polyhydroxybutyrate, polyhydroxyvalerate, polydioxanone, polyiminocarbonates, polyorthoesters, ethylene vinyl alcohol copolymer, L-polylactide, D,L-polylactide, polyglycolide, polycaprolactone, copolymers of lactide and glycolide, polymethylmethacrylate, poly(n-butyl)methacrylate, polyacrylates, polymethacrylates, elastomers, and mixtures thereof.

[0058] Representative elastomers include, but are not limited to, a thermoplastic elastomer material available under the trade name “C-FLEX” from Concept Polymer Technologies of Largo, Fla., polyether-amide thermoplastic elastomer, fluoroelastomers, fluorosilicone elastomer, sytrene-butadiene rubber, butadiene-styrene rubber, polyisoprene, neoprene (polychloroprene), ethylene-propylene elastomer, chloro-sulfonated polyethylene elastomer, butyl rubber, polysulfide elastomer, polyacrylate elastomer, nitrile, rubber, polyester, styrene, ethylene, propylene, butadiene and isoprene, polyester thermoplastic elastomer, and mixtures thereof.

[0059] The choice of the polymer in first layer 24 typically depends on the selection of the particular drug 16. For a drug 16 that is to be dissolved in the polymer, the factors to be considered in selecting an appropriate polymer include the molecular structure of both the polymer and the drug, the crystallinity or amorphousness of the polymer, the molecular weight of the drug (which is indicative of its size on a molecular level), and the solubility of the drug in the polymer. Examples of drug/polymer pairings include dexamethasone in silicone or polyurethanes or fluoroelastomer; taxol in ethylene vinyl acetate or L-polylactide or polycaprolactone or polyurethanes; rapamycin in polymethylmethacrylate or poly(n-butyl)methacrylate; tranilast in polyurethanes or ethylene vinyl acetate; and fluorouracil in polyurethanes.

[0060] Examples of drug 16 include antineoplastic, antimitotic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antiproliferative, antibiotic, antioxidant, and antiallergic substances as well as combinations thereof. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g., TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g., Taxotere® from Aventis S.A., Frankfurt, Germany), methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g., Adriamycin® from Pharmacia & Upjohn, Peapack, N.J.), and mitomycin (e.g., Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiinflammatory substances include estradiol. Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as Angiomax™ (Biogen, Inc., Cambridge, Mass.). Examples of such antiallergic substances include permirolast potassium and tranilast. Examples of such cytostatic or antiproliferative agents include actinomycin D as well as derivatives and analogs thereof (manufactured by Sigma-Aldrich, Milwaukee, Wis.; or COSMEGEN® available from Merck & Co., Inc., Whitehouse Station, N.J.), angiopeptin, mitomycin, angiotensin converting enzyme inhibitors such as captopril (e.g., Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g., Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J., calcium channel blockers (such as nifedipine), colchicine, fibrolast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMB-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide.

[0061] Other drugs or agents that may be used include, for example, alpha-interferon, genetically engineered epithelial cells, and dexamethasone. While the preventative and treatment properties of the foregoing drugs or agents are well-known to those of ordinary skill in the art, the substances or agents are provided by way of example and are not meant to be limiting. Other drugs that may be carried in a polymer coating are equally applicable for use with the present invention.

[0062] According to the present invention, the release rate of the drug typically will be controlled in part by the material selected for the barrier. For instance, the barrier material may be an inorganic compound, which is typically polar or ionic in nature. Generally, if the selected drug 16 is likewise polar or ionic in nature (e.g., cisplatin, fluoracil), then the solubility of drug 16 in barrier 28 will be higher, resulting in a higher diffusivity, and thus a faster rate of delivery of drug 16 through barrier 28 to internal target tissue area 50. Conversely, if the selected drug 16 is nonpolar, (e.g., TAXOL®, dexamethasone), then the solubility of drug 16 in barrier 28 will be lower, resulting in a lower diffusivity, and thus a lower rate of delivery of drug 16 through barrier 28 to internal target tissue area 50. However, this is not always the case. Titanium dioxide is a polar inorganic compound, but it has such a high degree of crystallinity, and an affinity for itself that other polar compounds (e.g., the drug to be delivered) do not necessarily dissolve into titanium dioxide very well.

[0063] FIG. 4 illustrates another embodiment of the present invention, wherein barrier 28 is composed of a number of discrete deposits above first layer 24. When using certain deposition methods, the first few atoms or molecules of barrier 28 deposited on first layer 24 form small nucleation sites 30 on the surface 29 of first layer 24. Barrier 28 may be made discontinuous by arresting the deposition process at the nucleation stage, as illustrated in FIG. 4. However, if the deposition is allowed to continue, nucleation sites 30 expand in surface area and eventually coalesce into a continuous film, as barrier 28 is illustrated in FIG. 3.

[0064] In the embodiment illustrated in FIG. 4, the rate of drug delivery from first layer 24 to internal tissue target area 50 is reduced primarily by the presence of nucleation sites 30. Nucleation sites 30 reduce the surface area available for drug 16 to diffuse from first layer 24 toward the internal tissue target area 50, because the vast majority of drug 16 will preferentially diffuse between nucleation sites 30 at spaces 32. While drug 16 may diffuse through nucleation sites 30, it will do so at a much slower rate. Drug 16 situated beneath nucleation site 30 will not proceed directly to tissue 50 through nucleation site 30, but will instead be directed by the diffusion gradient formed toward a space 32. Nucleation sites 30 thus may also increase the length and tortuosity of the average diffusion path taken by molecules of drug 16, again resulting in a slower rate of diffusion of drug 16 from first layer 24.

[0065] The release rate associated with the embodiment of FIG. 4 may be generally described by the following equation:
Release Rate=(1−A)Φ(t) (Equation 3)

[0066] where A=fraction of surface area covered by nucleation sites; and

[0067] Φ(t) is as defined in Equation 1.

Equation 3 assumes that there is no diffusion through nucleation sites 30. Again, this equation is provided as an explanatory aid, and does not in any way limit the invention.

[0068] Advantageously, in this embodiment, the rate of drug delivery (and thus, the effective treatment time) may be manipulated by controlling the number of nucleation sites 30 that are permitted to form on surface 29 of first layer 24. The number of nucleation sites may be controlled by controlling various deposition process parameters, such as deposition rate, substrate temperature, energy of the deposited atoms, substrate surface cleanliness and defects, angle of the incident atom flux, and substrate surface roughness.

[0069] The embodiment illustrated in FIG. 4 may be achieved by performing deposition processes that deposit layers of material by way of nucleation, such as cathodic arc sputtering, reactive sputtering, thermal evaporation and electron beam (e-beam) evaporation of materials such as gold, palladium, and aluminum.

[0070] The embodiment illustrated in FIG. 4 may also be achieved by depositing a continuous film, and then creating holes in that film. For example, metal films can be deposited with differing amounts of grain structure. An etching chemical (e.g., typically mixtures of mineral acids) may be used to preferentially etch between grains and remove some of the metal film. Alternately, a continuous film could be deposited, and holes made in that continuous film by, for example, ion milling, a laser, or electron beam machining. Another method for achieving this embodiment would be deposition of a continuous film, followed by mechanically stressing the film, so that the continuous film fractures at preselected locations.

[0071] FIG. 6 illustrates another embodiment of the invention, wherein first layer 24, and the barrier coating are not two discrete layers. Instead, the interface between first layer 24 and barrier 40 is irregular, because barrier 40 is blended with first layer 24 to form an intermixed zone 42 at and near the top surface of first layer 24. Intermixing of the barrier 40 with first layer 24 may result when barrier 40 is deposited using one of several methods, whereby the deposited inorganic materials actually penetrate into first layer 24, rather than merely adhering to the surface of first layer 24. These methods include, for example, ion implantation, plasma ion implantation, alkoxide hydrolysis, and electroless deposition. Intermixed zone 42 may include isolated bodies 43 of barrier material formed within first layer 24 and/or fingers 45 of barrier coating material extending into first layer 24.

[0072] The rate of drug delivery from first layer 24 to internal target tissue area 50 may be reduced in large part by at least two mechanisms in this embodiment. First, if drug 16 diffuses through the barrier material in intermixed zone 42, then drug 16 may have to follow a more tortuous diffusion path than drug 16 would otherwise follow, decreasing the diffusion rate. Second, if the barrier material in intermixed zone 42 acts as a complete barrier to diffusion, then the area normal to the direction of diffusion is significantly reduced, thus reducing the diffusion rate, in a manner similar to the nucleation sites in the embodiment illustrated in FIG. 4.

[0073] Meaningful quantitative or semiquantitative descriptions of drug release rates from the embodiment illustrated in FIG. 6 are difficult to provide, since the geometry of the intermixed zone 42 is highly variable. However, it can be stated that, regardless of the geometry of the intermixed zone, the rate of release of drug 16 from first layer 24 will be significantly reduced.

[0074] One of ordinary skill in the art will appreciate that, for all of the embodiments described herein, the thickness of the barrier used may be varied, with a corresponding change in the drug release rate. Generally, the thicker the barrier, the greater the reduction in the drug release rate. However, there is a practical limit on the thickness of the barrier to be applied to first layer 24. If the barrier becomes too thick, then, when subjected to stress from mechanical flexing or changes in temperature, internal stresses will build up within the barrier. When these internal stresses exceed the adhesion between the barrier and the underlying film, the barrier may fracture throughout. Small pieces of the barrier may then be lifted off from first layer 24. The pieces could enter the lumen of a blood vessel, and act as an embolus, with potentially very harmful effects on the patient.

EXAMPLE 1

Use of SiOx Film as a Barrier Coating to Reduce the Rate of Release of Nitric Oxide from a Polymer Coated Medical Device

[0075] Healthy endothelial cells located along the intima (the innermost layer of cells lining the blood vessels) produce a nearly constant supply of nitric oxide. Nitric oxide molecules signal the surrounding smooth muscle cells. We currently believe nitric oxide molecules also prevent the smooth muscle cells from migrating and/or proliferating, which, it is postulated, would reduce the incidence of restenosis following PTCA. To be effective in local delivery, nitric oxide would ideally be released over a period of weeks (e.g., four to eight weeks, generally, and in some cases, up to twelve weeks, depending on the patient). In accordance with one embodiment of the invention, a homogeneous film of non-stoichiometric silicon dioxide (known as SiO_x) is deposited as barrier coating 28 on first layer 24. First layer 24 contains drug 16, which in this case is nitric oxide or a molecule which releases nitric oxide.

[0076] Experimental data collected by others has shown that a polycarbonate film having an average molecular weight in the range of 20,000 to 40,000 g/mole has an oxygen (O₂) transmission rate of 1000 cm³/m²-atm-day. See, Erlat, et al., “Morphology and Gas Barrier Properties of Thin SiO_xCoatings on Polycarbonate: Correlations with Plasma-enhanced Chemical Vapor Deposition Conditions,” J. Mater. Res., Vol. 15, No. 3, March 2000. By depositing a SiO_xcoating having a thickness of approximately 30 nanometers (nm) on the polycarbonate, using plasma-enhanced chemical vapor deposition, the oxygen transmission rate was reduced by one order of magnitude to approximately 100 cm³/m²-atm-day. By increasing the thickness of the SiO_xcoating deposited to 60 nanometers, the oxygen transmission rate was further reduced by another order of magnitude, to approximately 10 cm³/m²-atm-day. A less dramatic reduction in oxygen transmission was observed with further increases in SiO_xcoating thickness.

[0077] Since oxygen (O₂) and nitric oxide (NO) are similar to each other in size and molecular weight, we anticipate that an implanted medical device (e.g., a stent or graft) having a SiO_xlayer provided atop a polymeric coating containing nitric oxide would cause a similar reduction in the rate at which nitric oxide is released from the polymeric material into a target tissue area. That is, the release rate of nitric oxide from the polymeric carrier could be reduced by a factor of 10 by depositing a SiO_xcoating that is 30 nanometers thick on the polymeric carrier, and reduced by a factor of 100 by depositing a SiO_xcoating 60 nanometers thick on the polymeric carrier. As a result, for a given mass of nitric oxide loaded into the polymer carrier, the period of time over which nitric oxide is released could be extended by factors of 10 and 100, respectively. Accordingly, the implantable medical device having such a polymer coating and barrier coating would be useful in providing localized drug delivery for an extended period to a patient after PTCA.

EXAMPLE 2

Use of Discontinuous Barrier Coating to Reduce the Rate of Release of Dexamethasone from a Silicone Polymer

[0078] Line A of FIG. 5 illustrates the release of dexamethasone acetate (C₂₂H₂₉FO₅), a synthetic steroid used as an anti-inflammatory agent, from collars made from a silicone polymer over a period of 25 days when the polymeric collars were immersed in saline solution at a temperature of 37° C. Each polymeric collar was loaded with approximately 0.25 mg of dexamethasone acetate. A total of twenty polymeric collars were tested, and the averaged results are shown. After 25 days, a total of 0.018 mg of dexamethesone had been released, on average, from each polymeric collar.

[0079] Assuming nucleation sites 30 of a barrier material were deposited on the silicone polymer in a manner similar to that illustrated in FIG. 4, so as to cover 50% of the available surface area, then the release rate would be reduced by 50%, with the result that the drug release curve would be predicted to appear as shown by line B of FIG. 5. That is, after 25 days, an average of 0.009 mg of dexamethasone would be released. Advantageously, the reduction in the drug release rate by 50% essentially means that the drug would be locally delivered to the body for a period of time twice as long, significantly extending the time of drug release.

[0080] Similarly, the process parameters could be controlled so that nucleation sites 30 cover 75% of surface 29 of first layer 24 (which FIG. 4 approximates). This would result in a drug delivery rate that is approximately 25% lower than that associated with the homogeneous film embodiment illustrated in FIG. 3.

EXAMPLE 3

Method for Producing a Titanium Oxide Barrier Coating on a Polymer-Coated Medical Device by Alkoxide Hydrolysis

[0081] One method by which the embodiment illustrated in FIG. 6 may be produced is alkoxide hydrolysis. If an implantable medical device having a first layer 24 is exposed to a humid environment and then immersed in a metal alkoxide solution, within seconds, metal oxide will be formed at or near the top surface of first layer 24 by reaction of the alkoxide with the water in the polymer coating. As long as the polymer contains some moisture (e.g., at least 1% by weight), the reaction can go forward. Examples of suitable metal alkoxides include titanium ethoxide and titanium propoxide.

[0082] A solution of titanium ethoxide is created in dry ethanol at concentrations from about 0.1% to 10%. A polymer coated stent is exposed to an environment with controlled relative humidity between 20% and 100% for between 0.5 and 60 minutes. The stent is then immersed in the alkoxide solution for between 1 and 60 seconds, and then removed. The excess alkoxide solution is rinsed off using ethanol or water. The stent is then dried in a suitable environment (temperature from 20° to 70° C. for 1 to 60 minutes).

EXAMPLE 4

Methods for Producing Barrier Coatings on a Polymer by Electroless Plating

[0083] Another method by which the embodiments illustrated in FIGS. 3 and 6 may be produced is reductive deposition in solution, or electroless plating of a material onto a polymer coated surface of an implantable medical device. Electroless plating uses a chemical reduction reaction to deposit metal on a substrate without the passage of an electric current. Nonconductive substrates, such as polymers, are readily plated by this method if the polymer is first catalytically activated. The polymer may be catalytically activated by, for example, immersing it in a colloidal solution containing palladium. This colloidal solution provides nucleation sites of palladium (in this instance) on the polymer prior to electroless deposition of the metal. Certain polymers require an etching step before activation.

[0084] Biocompatible inorganic barriers that may be deposited by electroless deposition include palladium (Pd) and gold (Au). Reducing agents for palladium include hypophosphite, amineborane, and hydrazine. Reducing agents for gold include borohydride, amineborane, and hydrazine. The principal reactions that are believed to occur during electroless palladium plating, using hypophosphite as a reducing agent in one commercial application, are shown below.
2H₂PO₂⁻+2H₂O→2HPO₃⁻²+4H⁺+2H⁻ (1)
Pd⁺⁺+2H⁻→Pd⁰+H₂ (2)
2H₂PO₂⁻+2H⁻→2P+4OH⁻+H₂ (3)

[0086] According to the authors, the hypophosphite ion is thought of as being catalytically oxidized (dehydrogenated) on the surface to be plated to release hydride ions (H⁻) which are then available for reduction of palladium ions at the surface. The products of the reactions are thus the palladium-phosphorus deposit, phosphite ions, hydrogen ions, and hydrogen gas. The phosphorus may be codeposited with palladium to the extent of 1 to 15 percent by weight by a mechanism shown in reaction (3) above.

[0087] For example, to provide a palladium barrier coating, an implantable medical device having a polymer coating with a finely etched surface is immersed in an aqueous solution of 5 g/L SnCl₂and 5 mL/L HCL for a period of about 5 minutes at 35° C. The implantable medical device is then immersed in a plating solution at a temperature of 50° C., the plating solution including 2 g/L of palladium chloride, 160 mL/L of ammonium hydroxide (27%), 26 g/L of ammonium chloride, and 10 g/L of sodium hyposphosphite.

[0088] To provide a gold barrier coating, an implantable medical device having a polymer coating with a finely etched surface is immersed in an aqueous solution of 5 g/L SnCl₂and 5 mL/L HCL for a period of about 5 minutes at 35° C. The implantable medical device is then immersed in a plating solution at a temperature of 75° C., the plating solution including 5.8 g/L of potassium gold cyanide, 13.0 g/L of potassium cyanide, and 21.6 g/L of potassium borohydride.

[0089] Codeposition of phosporus and boron may occur in the electroless plating process given above. In another process which is commercially available, a proprietary reducing reagent is used that yields an electroless deposit of pure palladium that is free of phosphorus or boron. The process is known as the Pallatec™ process, and is available from Atotech USA, Inc. of Somerset, N.J. This process reportedly involves the steps of acid cleaning, microetching, activation, and electroless deposition of palladium.

[0090] While particular embodiments of the present invention have been shown and described, various changes and modifications can be made without departing from this invention in its broader aspects. For instance, while we have discussed the invention in conjunction with stents and grafts, artisans will appreciate that the invention may be used with any implantable medical device that can be used in conjunction with a drug-loaded polymer for localized drug delivery. For example, such barrier coatings may be applied to drug-loaded polymer coatings on catheters, cerebrospinal fluid shunts, drug delivery pacemaker leads, defibrillation electrodes, artificial hips and bones, breast implants, and other implanted devices. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

Claims

What is claimed is:

1. An implantable medical device, comprising:

a substrate adapted to be implanted at a site in need of therapy;

a polymeric layer comprising poly(methylmethacrylate) or poly(butylmethacrylate) supported by the substrate, the polymeric layer containing rapamycin for administering rapamycin to the site in need of therapy by diffusing through the polymeric layer to the site; and

a barrier over at least a portion of the polymeric layer to reduce the rate of release of rapamycin from the implantable medical device.

2. The implantable medical device of claim 1, wherein the barrier degrades.

3. The implantable medical device of claim 1, wherein the polymeric layer additionally includes poly(ethylene co-vinyl acetate).

4. The implantable medical device of claim 1, wherein the device is a stent.

5. A method of making an implantable medical device, the method comprising:

forming a coating on the device, wherein the coating comprises poly(butyl methacrylate), rapamycin and poly(ethylene co-vinyl acetate); and

forming a barrier layer for reducing a rate of release of rapamycin after implantation of the device into a body of a patient.

6. The method of claim 5, wherein the coating is formed by applying a plurality of layers of poly(butyl methacrylate), rapamycin and poly(ethylene co-vinyl acetate) to the device.

7. The method of claim 5, wherein the device is a stent.

8. The implantable medical device of claim 1, wherein the barrier comprises a polymer.

9. The implantable medical device of claim 1, wherein the barrier comprises an inorganic material.

10. The implantable medical device of claim 3, wherein the barrier comprises a polymer and wherein the polymeric layer includes poly(butylmethacrylate).

11. The implantable medical device of claim 10, wherein the device is a stent.

12. The implantable medical device of claim 10, wherein the barrier is a homogeneous layer.

13. The implantable medical device of claim 1, wherein the barrier comprises a polymer; wherein the polymeric layer consists of poly(butylmethacrylate), poly(ethylene co-vinyl acetate), and rapamycin; and wherein the device is a stent.

14. The implantable medical device of claim 1, wherein the barrier comprises a metallic material.

15. The method of claim 5, wherein the barrier layer comprises a polymer.

16. The method of claim 5, wherein the barrier layer comprises a polymer and the device is a stent.

17. The method of claim 16, wherein the barrier layer is blended into the coating.

18. The method of claim 5, wherein the barrier layer comprises an inorganic material.

Patent Citations (469)

Patent	Date	Inventor	Cited By
US2072303(A)	1937-03-01	Herrmann et al.	Applicant
US2386454(A)	1945-10-01	Frosch et al.	Applicant
US3773737(A)	1973-11-01	Goodman et al.	Applicant
US3849514(A)	1974-11-01	Gray, Jr. et al.	Applicant
US4226243(A)	1980-10-01	Shalaby et al.	Applicant
US4329383(A)	1982-05-01	Joh	Applicant
US4343931(A)	1982-08-01	Barrows	Applicant
US4529792(A)	1985-07-01	Barrows	Applicant
US4611051(A)	1986-09-01	Hayes et al.	Applicant
US4656242(A)	1987-04-01	Swan et al.	Applicant
US4678468(A)	1987-07-01	Hiroyoshi	Applicant
US4733665(A)	1988-03-01	Palmaz	Applicant
US4800882(A)	1989-01-01	Gianturco	Applicant
US4816339(A)	1989-03-01	Tu et al.	Applicant
US4882168(A)	1989-11-01	Casey et al.	Applicant
US4886062(A)	1989-12-01	Wiktor	Applicant
US4931287(A)	1990-06-01	Bae et al.	Applicant
US4941870(A)	1990-07-01	Okada et al.	Applicant
US4977901(A)	1990-12-01	Ofstead	Applicant
US5019096(A)	1991-05-01	Fox, Jr. et al.	Applicant
US5064435(A)	1991-11-01	Porter	Applicant
US5071407(A)	1991-12-01	Termin et al.	Applicant
US5078736(A)	1992-01-01	Behl	Applicant
US5092841(A)	1992-03-01	Spears	Applicant
US5100992(A)	1992-03-01	Cohn et al.	Applicant
US5112457(A)	1992-05-01	Marchant	Applicant
US5133742(A)	1992-07-01	Pinchuk	Applicant
US5163952(A)	1992-11-01	Froix	Applicant
US5165919(A)	1992-11-01	Sasaki et al.	Applicant
US5219980(A)	1993-06-01	Swidler	Applicant
US5258020(A)	1993-11-01	Froix	Applicant
US5272012(A)	1993-12-01	Opolski	Applicant
US5292516(A)	1994-03-01	Viegas et al.	Applicant
US5298260(A)	1994-03-01	Viegas et al.	Applicant
US5300295(A)	1994-04-01	Viegas et al.	Applicant
US5306501(A)	1994-04-01	Viegas et al.	Applicant
US5306786(A)	1994-04-01	Moens et al.	Applicant
US5328471(A)	1994-07-01	Slepian	Applicant
US5330768(A)	1994-07-01	Park et al.	Applicant
US5344411(A)	1994-09-01	Domb et al.	Applicant
US5344425(A)	1994-09-01	Sawyer	Applicant
US5380299(A)	1995-01-01	Fearnot et al.	Applicant
US5417981(A)	1995-05-01	Endo et al.	Applicant
US5447724(A)	1995-09-01	Helmus et al.	Applicant
US5455040(A)	1995-10-01	Marchant	Applicant
US5462990(A)	1995-10-01	Hubbell et al.	Applicant
US5464650(A)	1995-11-01	Berg et al.	Applicant
US5474089(A)	1995-12-01	Waynant	Applicant
US5485496(A)	1996-01-01	Lee et al.	Applicant
US5516881(A)	1996-05-01	Lee et al.	Applicant
US5569463(A)	1996-10-01	Helmus et al.	Applicant
US5571086(A)	1996-11-01	Kaplan et al.	Applicant
US5576072(A)	1996-11-01	Hostettler et al.	Applicant
US5578073(A)	1996-11-01	Haimovich et al.	Applicant
US5584877(A)	1996-12-01	Miyake et al.	Applicant
US5605696(A)	1997-02-01	Eury et al.	Applicant
US5607467(A)	1997-03-01	Froix	Applicant
US5609629(A)	1997-03-01	Fearnot et al.	Applicant
US5610241(A)	1997-03-01	Lee et al.	Applicant
US5616338(A)	1997-04-01	Fox, Jr. et al.	Applicant
US5624411(A)	1997-04-01	Tuch	Applicant
US5628730(A)	1997-05-01	Shapland et al.	Applicant
US5644020(A)	1997-07-01	Timmermann et al.	Applicant
US5649977(A)	1997-07-01	Campbell	Applicant
US5658995(A)	1997-08-01	Kohn et al.	Applicant
US5662960(A)	1997-09-01	Hostettler et al.	Applicant
US5667767(A)	1997-09-01	Greff et al.	Applicant
US5670558(A)	1997-09-01	Onishi et al.	Applicant
US5674242(A)	1997-10-01	Phan et al.	Applicant
US5676685(A)	1997-10-01	Razavi	Applicant
US5679400(A)	1997-10-01	Tuch	Applicant
US5700286(A)	1997-12-01	Tartaglia et al.	Applicant
US5702754(A)	1997-12-01	Zhong	Applicant
US5711958(A)	1998-01-01	Cohn et al.	Applicant
US5716981(A)	1998-02-01	Hunter et al.	Applicant
US5721131(A)	1998-02-01	Rudolph et al.	Applicant
US5723219(A)	1998-03-01	Kolluri et al.	Applicant
US5728152(A)	1998-03-01	Mirsch, II et al.	Applicant
US5735897(A)	1998-04-01	Buirge	Applicant
US5746998(A)	1998-05-01	Torchilin et al.	Applicant
US5759205(A)	1998-06-01	Valentini	Applicant
US5762638(A)	1998-06-01	Shikani et al.	Applicant
US5776184(A)	1998-07-01	Tuch	Applicant
US5783657(A)	1998-07-01	Pavlin et al.	Applicant
US5788979(A)	1998-08-01	Alt et al.	Applicant
US5792550(A)	1998-08-01	Phillips et al.	Applicant
US5800392(A)	1998-09-01	Racchini	Applicant
US5820917(A)	1998-10-01	Tuch	Applicant
US5824048(A)	1998-10-01	Tuch	Applicant
US5824049(A)	1998-10-01	Ragheb et al.	Applicant
US5830178(A)	1998-11-01	Jones et al.	Applicant
US5830430(A)	1998-11-01	Unger et al.	Applicant
US5837008(A)	1998-11-01	Berg et al.	Applicant
US5837313(A)	1998-11-01	Ding et al.	Applicant
US5843156(A)	1998-12-01	Slepian et al.	Applicant
US5849035(A)	1998-12-01	Pathak et al.	Applicant
US5849368(A)	1998-12-01	Hostettler et al.	Applicant
US5849859(A)	1998-12-01	Acemoglu	Applicant
US5851508(A)	1998-12-01	Greff et al.	Applicant
US5854376(A)	1998-12-01	Higashi	Applicant
US5854382(A)	1998-12-01	Loomis	Applicant
US5855563(A)	1999-01-01	Kaplan et al.	Applicant
US5855599(A)	1999-01-01	Wan	Applicant
US5857998(A)	1999-01-01	Barry	Applicant
US5858746(A)	1999-01-01	Hubbell et al.	Applicant
US5858990(A)	1999-01-01	Walsh	Applicant
US5865814(A)	1999-02-01	Tuch	Applicant
US5869127(A)	1999-02-01	Zhong	Applicant
US5873904(A)	1999-02-01	Ragheb et al.	Applicant
US5876433(A)	1999-03-01	Lunn	Applicant
US5877224(A)	1999-03-01	Brocchini et al.	Applicant
US5879713(A)	1999-03-01	Roth et al.	Applicant
US5895420(A)	1999-04-01	Mirsch, II et al.	Applicant
US5898066(A)	1999-04-01	Benowitz et al.	Applicant
US5899935(A)	1999-05-01	Ding	Applicant
US5902875(A)	1999-05-01	Roby et al.	Applicant
US5905168(A)	1999-05-01	Dos Santos et al.	Applicant
US5910564(A)	1999-06-01	Gruning et al.	Applicant
US5911702(A)	1999-06-01	Romley et al.	Applicant
US5914387(A)	1999-06-01	Roby et al.	Applicant
US5919570(A)	1999-07-01	Hostettler et al.	Applicant
US5919893(A)	1999-07-01	Roby et al.	Applicant
US5925720(A)	1999-07-01	Kataoka et al.	Applicant
US5932299(A)	1999-08-01	Katoot	Applicant
US5951458(A)	1999-09-01	Hastings et al.	Applicant
US5955509(A)	1999-09-01	Webber et al.	Applicant
US5958385(A)	1999-09-01	Tondeur et al.	Applicant
US5961547(A)	1999-10-01	Razavi	Applicant
US5962007(A)	1999-10-01	Cooper et al.	Applicant
US5962138(A)	1999-10-01	Kolluri et al.	Applicant
US5971954(A)	1999-10-01	Conway et al.	Applicant
US5980928(A)	1999-11-01	Terry	Applicant
US5980972(A)	1999-11-01	Ding	Applicant
US5997517(A)	1999-12-01	Whitbourne	Applicant
US6005020(A)	1999-12-01	Loomis	Applicant
US6010530(A)	2000-01-01	Goicoechea	Applicant
US6011125(A)	2000-01-01	Lohmeijer et al.	Applicant
US6013780(A)	2000-01-01	Neufeld et al.	Applicant
US6015541(A)	2000-01-01	Greff et al.	Applicant
US6017577(A)	2000-01-01	Hostettler et al.	Applicant
US6022901(A)	2000-02-01	Goodman	Applicant
US6026316(A)	2000-02-01	Kucharczyk et al.	Applicant
US6028164(A)	2000-02-01	Loomis	Applicant
US6030656(A)	2000-02-01	Hostettler et al.	Applicant
US6033582(A)	2000-03-01	Lee et al.	Applicant
US6034204(A)	2000-03-01	Mohr et al.	Applicant
US6040058(A)	2000-03-01	Hostettler et al.	Applicant
US6042875(A)	2000-03-01	Ding et al.	Applicant
US6051576(A)	2000-04-01	Ashton et al.	Applicant
US6051648(A)	2000-04-01	Rhee et al.	Applicant
US6054553(A)	2000-04-01	Groth et al.	Applicant
US6056938(A)	2000-05-01	Unger et al.	Applicant
US6056993(A)	2000-05-01	Leidner et al.	Applicant
US6060451(A)	2000-05-01	DiMaio et al.	Applicant
US6060518(A)	2000-05-01	Kabanov et al.	Applicant
US6061587(A)	2000-05-01	Kucharczyk et al.	Applicant
US6080488(A)	2000-06-01	Hostettler et al.	Applicant
US6086773(A)	2000-07-01	Dufresne et al.	Applicant
US6096070(A)	2000-08-01	Ragheb et al.	Applicant
US6096726(A)	2000-08-01	Opolski	Applicant
US6099562(A)	2000-08-01	Ding et al.	Applicant
US6102046(A)	2000-08-01	Weinstein et al.	Applicant
US6110188(A)	2000-08-01	Narciso, Jr.	Applicant
US6110483(A)	2000-08-01	Whitbourne et al.	Applicant
US6113629(A)	2000-09-01	Ken	Applicant
US6120491(A)	2000-09-01	Kohn et al.	Applicant
US6120536(A)	2000-09-01	Ding et al.	Applicant
US6120788(A)	2000-09-01	Barrows	Applicant
US6120904(A)	2000-09-01	Hostettler et al.	Applicant
US6121027(A)	2000-09-01	Clapper et al.	Applicant
US6126649(A)	2000-10-01	VanTassel et al.	Applicant
US6129761(A)	2000-10-01	Hubbell	Applicant
US6136006(A)	2000-10-01	Johnson et al.	Applicant
US6136333(A)	2000-10-01	Cohn et al.	Applicant
US6140452(A)	2000-10-01	Felt et al.	Applicant
US6143354(A)	2000-11-01	Koulik et al.	Applicant
US6153252(A)	2000-11-01	Hossainy et al.	Applicant
US6156064(A)	2000-12-01	Chouinard	Applicant
US6156350(A)	2000-12-01	Constantz	Applicant
US6159232(A)	2000-12-01	Nowakowski	Applicant
US6159978(A)	2000-12-01	Myers et al.	Applicant
US6162244(A)	2000-12-01	Braun et al.	Applicant
US6165212(A)	2000-12-01	Dereume et al.	Applicant
US6172167(B1)	2001-01-01	Stapert et al.	Applicant
US6177523(B1)	2001-01-01	Reich et al.	Applicant
US6178346(B1)	2001-01-01	Amundson et al.	Applicant
US6179817(B1)	2001-01-01	Zhong	Applicant
US6180632(B1)	2001-01-01	Myers et al.	Applicant
US6183469(B1)	2001-02-01	Thapliyal et al.	Applicant
US6197051(B1)	2001-03-01	Zhong	Applicant
US6203551(B1)	2001-03-01	Wu	Applicant
US6211247(B1)	2001-04-01	Goodman	Applicant
US6211249(B1)	2001-04-01	Cohn et al.	Applicant
US6214901(B1)	2001-04-01	Chudzik et al.	Applicant
US6231600(B1)	2001-05-01	Zhong	Applicant
US6238364(B1)	2001-05-01	Becker	Applicant
US6240616(B1)	2001-06-01	Yan	Applicant
US6245753(B1)	2001-06-01	Byun et al.	Applicant
US6245760(B1)	2001-06-01	He et al.	Applicant
US6248129(B1)	2001-06-01	Froix	Applicant
US6249952(B1)	2001-06-01	Ding	Applicant
US6251136(B1)	2001-06-01	Guruwaiya et al.	Applicant
US6254632(B1)	2001-07-01	Wu et al.	Applicant
US6254634(B1)	2001-07-01	Anderson et al.	Applicant
US6258121(B1)	2001-07-01	Yang et al.	Applicant
US6258371(B1)	2001-07-01	Koulik et al.	Applicant
US6261320(B1)	2001-07-01	Tam et al.	Applicant
US6262034(B1)	2001-07-01	Mathiowitz et al.	Applicant
US6265016(B1)	2001-07-01	Hostettler et al.	Applicant
US6265199(B1)	2001-07-01	Sheppard et al.	Applicant
US6270788(B1)	2001-08-01	Koulik et al.	Applicant
US6273913(B1)	2001-08-01	Wright et al.	Examiner
US6274164(B1)	2001-08-01	Novich	Applicant
US6277449(B1)	2001-08-01	Kolluri et al.	Applicant
US6283947(B1)	2001-09-01	Mirzaee	Applicant
US6283949(B1)	2001-09-01	Roorda	Applicant
US6283951(B1)	2001-09-01	Flaherty et al.	Applicant
US6284305(B1)	2001-09-01	Ding et al.	Applicant
US6287249(B1)	2001-09-01	Tam et al.	Applicant
US6287628(B1)	2001-09-01	Hossainy et al.	Applicant
US6290729(B1)	2001-09-01	Slepian et al.	Applicant
US6299604(B1)	2001-10-01	Ragheb et al.	Applicant
US6302875(B1)	2001-10-01	Makower et al.	Applicant
US6306176(B1)	2001-10-01	Whitbourne	Applicant
US6306177(B1)	2001-10-01	Felt et al.	Applicant
US6316522(B1)	2001-11-01	Loomis et al.	Applicant
US6322771(B1)	2001-11-01	Linden et al.	Applicant
US6331313(B1)	2001-12-01	Wong et al.	Applicant
US6334867(B1)	2002-01-01	Anson	Applicant
US6335029(B1)	2002-01-01	Kamath et al.	Examiner
US6344035(B1)	2002-02-01	Chudzik et al.	Applicant
US6346110(B2)	2002-02-01	Wu	Applicant
US6358556(B1)	2002-03-01	Ding et al.	Applicant
US6379381(B1)	2002-04-01	Hossainy et al.	Applicant
US6387379(B1)	2002-05-01	Goldberg et al.	Applicant
US6391052(B2)	2002-05-01	Buirge	Applicant
US6395326(B1)	2002-05-01	Castro et al.	Applicant
US6410044(B1)	2002-06-01	Chudzik	Applicant
US6419692(B1)	2002-07-01	Yang et al.	Applicant
US6451373(B1)	2002-09-01	Hossainy et al.	Applicant
US6482834(B2)	2002-11-01	Spada et al.	Applicant
US6494862(B1)	2002-12-01	Ray et al.	Applicant
US6503538(B1)	2003-01-01	Chu et al.	Applicant
US6503556(B2)	2003-01-01	Harish et al.	Applicant
US6503954(B1)	2003-01-01	Bhat et al.	Applicant
US6506437(B1)	2003-01-01	Harish et al.	Applicant
US6524347(B1)	2003-02-01	Myers et al.	Applicant
US6527801(B1)	2003-03-01	Dutta	Applicant
US6527863(B1)	2003-03-01	Pacetti et al.	Applicant
US6528526(B1)	2003-03-01	Myers et al.	Applicant
US6530950(B1)	2003-03-01	Alvarado et al.	Applicant
US6530951(B1)	2003-03-01	Bates et al.	Applicant
US6540776(B2)	2003-04-01	Sanders Millare et al.	Applicant
US6544223(B1)	2003-04-01	Kokish	Applicant
US6544543(B1)	2003-04-01	Mandrusov et al.	Applicant
US6544582(B1)	2003-04-01	Yoe	Applicant
US6555157(B1)	2003-04-01	Hossainy	Applicant
US6558733(B1)	2003-05-01	Hossainy et al.	Applicant
US6565659(B1)	2003-05-01	Pacetti et al.	Applicant
US6572644(B1)	2003-06-01	Moein	Applicant
US6585755(B2)	2003-07-01	Jackson et al.	Applicant
US6585765(B1)	2003-07-01	Hossainy et al.	Applicant
US6585926(B1)	2003-07-01	Mirzaee	Applicant
US6605154(B1)	2003-08-01	Villareal	Applicant
US6616765(B1)	2003-09-01	Hossaony et al.	Applicant
US6623448(B2)	2003-09-01	Slater	Applicant
US6625486(B2)	2003-09-01	Lundkvist et al.	Applicant
US6645135(B1)	2003-11-01	Bhat	Applicant
US6645195(B1)	2003-11-01	Bhat et al.	Applicant
US6656216(B1)	2003-12-01	Hossainy et al.	Applicant
US6656506(B1)	2003-12-01	Wu et al.	Applicant
US6660034(B1)	2003-12-01	Mandrusov et al.	Applicant
US6663662(B2)	2003-12-01	Pacetti et al.	Applicant
US6663880(B1)	2003-12-01	Roorda et al.	Applicant
US6673154(B1)	2004-01-01	Pacetti et al.	Applicant
US6673385(B1)	2004-01-01	Ding et al.	Applicant
US6689099(B2)	2004-02-01	Mirzaee	Applicant
US6695920(B1)	2004-02-01	Pacetti et al.	Applicant
US6706013(B1)	2004-03-01	Bhat et al.	Applicant
US6709514(B1)	2004-03-01	Hossainy	Applicant
US6712845(B2)	2004-03-01	Hossainy	Applicant
US6713119(B2)	2004-03-01	Hossainy et al.	Applicant
US6716444(B1)	2004-04-01	Castro et al.	Applicant
US6723120(B2)	2004-04-01	Yan	Applicant
US6733768(B2)	2004-05-01	Hossainy et al.	Applicant
US6740040(B1)	2004-05-01	Mandrusov et al.	Applicant
US6743462(B1)	2004-06-01	Pacetti	Applicant
US6749626(B1)	2004-06-01	Bhat et al.	Applicant
US6753071(B1)	2004-06-01	Pacetti	Applicant
US6758859(B1)	2004-07-01	Dang et al.	Applicant
US6759054(B2)	2004-07-01	Chen et al.	Applicant
US6764505(B1)	2004-07-01	Hossainy et al.	Applicant
US6790228(B2)	2004-09-01	Hossainy et al.	Applicant
US6861088(B2)	2005-03-01	Weber et al.	Applicant
US6865810(B2)	2005-03-01	Stinson	Applicant
US6869443(B2)	2005-03-01	Buscemi et al.	Applicant
US6878160(B2)	2005-04-01	Gilligan et al.	Applicant
US6887270(B2)	2005-05-01	Miller et al.	Applicant
US6887485(B2)	2005-05-01	Fitzhugh et al.	Applicant
US6890546(B2)	2005-05-01	Mollison et al.	Applicant
US6899731(B2)	2005-05-01	Li et al.	Applicant
US6953560(B1)	2005-10-01	Castro et al.	Examiner
US2001/0007083(A1)	2001-07-01	Roorda	Applicant
US2001/0014717(A1)	2001-08-01	Hossainy et al.	Applicant
US2001/0018469(A1)	2001-08-01	Chen et al.	Applicant
US2001/0020011(A1)	2001-09-01	Mathiowitz et al.	Applicant
US2001/0029351(A1)	2001-10-01	Falotico et al.	Applicant
US2001/0037145(A1)	2001-11-01	Guruwaiya et al.	Applicant
US2001/0051608(A1)	2001-12-01	Mathiowitz et al.	Applicant
US2002/0005206(A1)	2002-01-01	Falotico et al.	Applicant
US2002/0007213(A1)	2002-01-01	Falotico et al.	Applicant
US2002/0007214(A1)	2002-01-01	Falotico	Applicant
US2002/0007215(A1)	2002-01-01	Falotico et al.	Applicant
US2002/0009604(A1)	2002-01-01	Zamora et al.	Applicant
US2002/0016625(A1)	2002-02-01	Falotico et al.	Applicant
US2002/0032414(A1)	2002-03-01	Ragheb et al.	Applicant
US2002/0032434(A1)	2002-03-01	Chudzik et al.	Applicant
US2002/0051730(A1)	2002-05-01	Bodnar et al.	Applicant
US2002/0071822(A1)	2002-06-01	Uhrich	Applicant
US2002/0077693(A1)	2002-06-01	Barclay et al.	Applicant
US2002/0082679(A1)	2002-06-01	Sirhan et al.	Applicant
US2002/0087123(A1)	2002-07-01	Hossainy et al.	Applicant
US2002/0091433(A1)	2002-07-01	Ding et al.	Applicant
US2002/0094440(A1)	2002-07-01	Llanos et al.	Applicant
US2002/0111590(A1)	2002-08-01	Davila et al.	Applicant
US2002/0120326(A1)	2002-08-01	Michal	Applicant
US2002/0123801(A1)	2002-09-01	Pacetti et al.	Applicant
US2002/0142039(A1)	2002-10-01	Claude	Applicant
US2002/0155212(A1)	2002-10-01	Hossainy	Applicant
US2002/0165608(A1)	2002-11-01	Llanos et al.	Applicant
US2002/0176849(A1)	2002-11-01	Slepian	Applicant
US2002/0183581(A1)	2002-12-01	Yoe et al.	Applicant
US2002/0188037(A1)	2002-12-01	Chudzik et al.	Applicant
US2002/0188277(A1)	2002-12-01	Roorda et al.	Applicant
US2003/0004141(A1)	2003-01-01	Brown	Applicant
US2003/0028243(A1)	2003-02-01	Bates et al.	Applicant
US2003/0028244(A1)	2003-02-01	Bates et al.	Applicant
US2003/0031780(A1)	2003-02-01	Chudzik et al.	Applicant
US2003/0032767(A1)	2003-02-01	Tada et al.	Applicant
US2003/0036794(A1)	2003-02-01	Ragheb et al.	Applicant
US2003/0039689(A1)	2003-02-01	Chen et al.	Applicant
US2003/0040712(A1)	2003-02-01	Ray et al.	Applicant
US2003/0040790(A1)	2003-02-01	Furst	Applicant
US2003/0059520(A1)	2003-03-01	Chen et al.	Applicant
US2003/0060877(A1)	2003-03-01	Falotico et al.	Applicant
US2003/0065377(A1)	2003-04-01	Davila et al.	Applicant
US2003/0072868(A1)	2003-04-01	Harish et al.	Applicant
US2003/0073961(A1)	2003-04-01	Happ	Applicant
US2003/0083646(A1)	2003-05-01	Sirhan et al.	Applicant
US2003/0083739(A1)	2003-05-01	Cafferata	Applicant
US2003/0097088(A1)	2003-05-01	Pacetti	Applicant
US2003/0097173(A1)	2003-05-01	Dutta	Applicant
US2003/0099712(A1)	2003-05-01	Jayaraman	Applicant
US2003/0105518(A1)	2003-06-01	Dutta	Applicant
US2003/0113439(A1)	2003-06-01	Pacetti et al.	Applicant
US2003/0150380(A1)	2003-08-01	Yoe	Applicant
US2003/0157241(A1)	2003-08-01	Hossainy et al.	Applicant
US2003/0158517(A1)	2003-08-01	Kokish	Applicant
US2003/0190406(A1)	2003-10-01	Hossainy et al.	Applicant
US2003/0207020(A1)	2003-11-01	Villareal	Applicant
US2003/0211230(A1)	2003-11-01	Pacetti et al.	Applicant
US2004/0018296(A1)	2004-01-01	Castro et al.	Applicant
US2004/0029952(A1)	2004-02-01	Chen et al.	Applicant
US2004/0047978(A1)	2004-03-01	Hossainy et al.	Applicant
US2004/0047980(A1)	2004-03-01	Pacetti et al.	Applicant
US2004/0052858(A1)	2004-03-01	Wu et al.	Applicant
US2004/0052859(A1)	2004-03-01	Wu et al.	Applicant
US2004/0054104(A1)	2004-03-01	Pacetti	Applicant
US2004/0060508(A1)	2004-04-01	Pacetti et al.	Applicant
US2004/0062853(A1)	2004-04-01	Pacetti et al.	Applicant
US2004/0063805(A1)	2004-04-01	Pacetti et al.	Applicant
US2004/0071861(A1)	2004-04-01	Mandrusov et al.	Applicant
US2004/0072922(A1)	2004-04-01	Hossainy et al.	Applicant
US2004/0073298(A1)	2004-04-01	Hossainy	Applicant
US2004/0086542(A1)	2004-05-01	Hossainy et al.	Applicant
US2004/0086550(A1)	2004-05-01	Roorda et al.	Applicant
US2004/0096504(A1)	2004-05-01	Michal	Applicant
US2004/0098117(A1)	2004-05-01	Hossainy et al.	Applicant
US2005/0037052(A1)	2005-02-01	Udipi et al.	Applicant
US2005/0038134(A1)	2005-02-01	Loomis et al.	Applicant
US2005/0038497(A1)	2005-02-01	Neuendorf et al.	Applicant
US2005/0043786(A1)	2005-02-01	Chu et al.	Applicant
US2005/0049693(A1)	2005-03-01	Walker	Applicant
US2005/0049694(A1)	2005-03-01	Neary	Applicant
US2005/0054774(A1)	2005-03-01	Kangas	Applicant
US2005/0055044(A1)	2005-03-01	Kangas	Applicant
US2005/0055078(A1)	2005-03-01	Campbell	Applicant
US2005/0060020(A1)	2005-03-01	Jenson	Applicant
US2005/0064088(A1)	2005-03-01	Fredrickson	Applicant
US2005/0065501(A1)	2005-03-01	Wallace	Applicant
US2005/0065545(A1)	2005-03-01	Wallace	Applicant
US2005/0065593(A1)	2005-03-01	Chu et al.	Applicant
US2005/0074406(A1)	2005-04-01	Couvillon, Jr. et al.	Applicant
US2005/0074545(A1)	2005-04-01	Thomas	Applicant
US2005/0075714(A1)	2005-04-01	Cheng et al.	Applicant
US2005/0079274(A1)	2005-04-01	Palasis et al.	Applicant
US2005/0084515(A1)	2005-04-01	Udipi et al.	Applicant
US2005/0106210(A1)	2005-05-01	Ding et al.	Applicant
US2005/0113903(A1)	2005-05-01	Rosenthal et al.	Applicant
DE4224401	1994-01-01		Applicant
EP301856	1989-02-01		Applicant
EP396429	1990-11-01		Applicant
EP514406	1992-11-01		Applicant
EP604022	1994-06-01		Applicant
EP623354	1994-11-01		Applicant
EP665023	1995-08-01		Applicant
EP701802	1996-03-01		Applicant
EP716836	1996-06-01		Applicant
EP809999	1997-12-01		Applicant
EP832655	1998-04-01		Applicant
EP850651	1998-07-01		Applicant
EP879595	1998-11-01		Applicant
EP910584	1999-04-01		Applicant
EP923953	1999-06-01		Applicant
EP953320	1999-11-01		Applicant
EP970711	2000-01-01		Applicant
EP982041	2000-03-01		Applicant
EP1023879	2000-08-01		Applicant
EP1192957	2002-04-01		Applicant
EP1273314	2003-01-01		Applicant
JP2001-190687	2001-07-01		Applicant
SU872531	1981-10-01		Applicant
SU876663	1981-10-01		Applicant
SU905228	1982-02-01		Applicant
SU790725	1983-02-01		Applicant
SU1016314	1983-05-01		Applicant
SU811750	1983-09-01		Applicant
SU1293518	1987-02-01		Applicant
WO91/12846	1991-09-01		Applicant
WO94/09760	1994-05-01		Applicant
WO95/10989	1995-04-01		Applicant
WO95/24929	1995-09-01		Applicant
WO96/40174	1996-12-01		Applicant
WO97/10011	1997-03-01		Applicant
WO97/45105	1997-12-01		Applicant
WO97/46590	1997-12-01		Applicant
WO98/08463	1998-03-01		Applicant
WO98/17331	1998-04-01		Applicant
WO98/32398	1998-07-01		Applicant
WO98/36784	1998-08-01		Applicant
WO99/01118	1999-01-01		Applicant
WO99/38546	1999-08-01		Applicant
WO99/63981	1999-12-01		Applicant
WO/02599	2000-01-01		Applicant
WO/12147	2000-03-01		Applicant
WO/18446	2000-04-01		Applicant
WO/64506	2000-11-01		Applicant
WO1/01890	2001-01-01		Applicant
WO1/15751	2001-03-01		Applicant
WO1/17577	2001-03-01		Applicant
WO1/45763	2001-06-01		Applicant
WO1/49338	2001-07-01		Applicant
WO1/51027	2001-07-01		Applicant
WO1/74414	2001-10-01		Applicant
WO2/03890	2002-01-01		Applicant
WO2/26162	2002-04-01		Applicant
WO2/34311	2002-05-01		Applicant
WO2/056790	2002-07-01		Applicant
WO2/058753	2002-08-01		Applicant
WO2/102283	2002-12-01		Applicant
WO3/000308	2003-01-01		Applicant
WO3/022323	2003-03-01		Applicant
WO3/028780	2003-04-01		Applicant
WO3/037223	2003-05-01		Applicant
WO3/039612	2003-05-01		Applicant
WO3/080147	2003-10-01		Applicant
WO3/082368	2003-10-01		Applicant
WO4/000383	2003-12-01		Applicant
WO2004/009145	2004-01-01		Applicant

Non-Patent Literature (53)

U.S. Appl. No. 09/894,293, filed Jun. 27, 2001, Roorda.Applicant
U.S. Appl. No. 10/176,504, filed Jun. 21, 2002, Roorda et al.Applicant
U.S. Appl. No. 10/176,510, filed Jun. 21, 2002, Hossainy et al.Applicant
U.S. Appl. No. 10/177,117, filed Jun. 21, 2002, Hossainy.Applicant
U.S. Appl. No. 10/177,154, filed Jun. 21, 2002, Hossainy et al.Applicant
U.S. Appl. No. 10/198,912, filed Jul. 19, 2002, Ding et al.Applicant
U.S. Appl. No. 10/320,899, filed Dec. 16, 2002, Shah et al.Applicant
U.S. Appl. No. 10/428,691, filed May 1, 2003, Pacetti.Applicant
Anonymous, Cardiologists Draw—Up the Dream Stent, Clinica 710:15 (Jun. 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959, printed Aug. 25, 2003 (2 pages).Applicant
Anonymous, Heparin-coated stents cut complications by 30%, Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753, printed Aug. 25, 2003, (2 pages).Applicant
Anonymous, Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent (Abstract 434009), Res. Disclos. pp. 974-975 (Jun. 2000).Applicant
Anonymous, Stenting continues to dominate cardiology, Clinica 720:22 (Sep. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752, printed Aug. 25, 2003 (2 pages).Applicant
Aoyagi et al., Preparation of cross-linked aliphatic polyester and application to thermo-responsive material, Journal of Controlled Release 32:87-96 (1994).Applicant
Atotech, Pallatect™ A Process for Autocatalytic Deposition of Palladium, http://www.insulectro.com/Pallatect.pdf , printed Mar. 17, 2004 (4 pages).Applicant
Atotech, Atotech Global-Home, http://www.atotech.com/start.php3?cl—my13 id=30574, printed Mar. 17, 2004 (1 page).Applicant
Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2): 252A (Abstract) (Feb. 1989).Applicant
Barbucci et al., Coating of commercially available materials with a new heparinizable material, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).Applicant
Baudrand et al., Electroless Palladium, Past and FutureProceedings of the AESF annual technical conference American Electroplaters and Surface Finishers Society, 1999, pp. 49-51.Applicant
Chemical Business Newsbase, “Headline: Modern Plastics International: New PET barrier technologies show promise in beer bottles”, Copyright 2000 FT Asia Intelligence Wire, Mar. 10, 2000 (1 page).Applicant
Chung et al., Inner core segment design for drug delivery control of thermo-responsive polymeric micelles, Journal of Controlled Release 65:93-103 (2000).Applicant
Dev et al., Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).Applicant
Dichek et al., Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells, Circ. 80(5):1347-1353 (Nov. 1989).Applicant
DNP Products & Services—Packaging, “Barrier Carton for Liquid L-Carton L-Barrier L-Alumi,” http://www.dnp.co.jp/international/pack/carton/carton—1.html, printed Mar. 17, 2004 (1 page).Applicant
DNP Products & Services—Packaging, “Barrier Carton for Liquid L-Carton L-Barrier L-Alumi,” http://www.dnp.co.jp/international/pack/carton/carton—2.html, printed Mar. 17, 2004 (2 pages).Applicant
DNP Products & Services—Packaging, “Barrier Carton for Liquid L-Carton L-Barrier L-Alumi,” http://www.dnp.co.jp/international/pack/carton/carton—3.html, printed Mar. 17, 2004 (1 page).Applicant
Eigler et al., Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin, JACC, 4A (701-1), Abstract (Feb. 1994).Applicant
Electro-Coatings of Iowa, Inc., “Kanigen® Electroless Nickel Alloy,” http://www.platingforindustry.com/electrocoatings/kantech.htm, printed Mar. 17, 2004 (3 pages).Applicant
Erlat et al., Morphology And Gas Barrier Properties Of Thin SiOx Coatings On Polycarbonate: Correlations With Plasma-Enhanced Chemical Vapor Deposition Conditions, J. Mater. Res., vol. 15, No. 3, Mar. 2000, pp. 704-717.Applicant
Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sep. 1991).Applicant
Herdeg et al., Antiproliferative Stent Coatings: Taxol and Related Compounds, Semin. Intervent. Cardiol. 3:197-199 (1998).Applicant
Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).Applicant
Kataoka et al., Block copolymer micelles as vehicles for drug delivery, Journal of Controlled Release 24:119-132 (1993).Applicant
Levy et al., Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).Applicant
Liu et al., Drug release characteristics of unimolecular polymeric micelles, Journal of Controlled Release 68:167-174 (2000).Applicant
Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).Applicant
Matsumaru et al., Embolic Materials for Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).Applicant
Mitsubishi Chemical Kohjin PAX Corporation, “Transparent Excellent Gas Barrier Plastic Film . . . Techbarrier®,” http://www.techbarrier.com/techbarrier/index.htm, printed Mar. 17, 2004 (3 pages).Applicant
Mitsubishi Chemical Kohjin PAX Corporation, “Techbarrier®-S,” http://www.techbarrier.com/techbarrier/tech-s.htm, printed Mar. 17, 2004 (2 pages).Applicant
Mitsubishi Chemical Kohjin PAX Corporation, “How to Handle and Convert Techbarrier®,” http://www.techbarrier.com/techbarrier/tech-kakou.htm, printed Mar. 17, 2004 (2 pages).Applicant
Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).Applicant
Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).Applicant
Modern Plastics, New PET Barrier Technologies Show Promise in Beer Bottle Advances to be on Tap At Industry Event, http://www.modplas.com/news/month—0100/gr01.htm, printed Dec. 3, 2002 (6 pages).Applicant
Nordrehaug et al., A novel biocompatible coating applied to coronary stents, EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).Applicant
Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).Applicant
Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, vol. XXXIX(2):129-140 (Sep./Oct. 1996).Applicant
Pharmaceutical & Medical Packaging News, “Film Preserves Blood Substitute,” http://www.devicelink.com/grabber.php3?URL=http:www.devicelink.com/pmpn/achive, printed Dec. 10, 2003 (3 pages).Applicant
Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).Applicant
Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).Applicant
Shigeno, Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor, Chemical Abstract 125:212307 (1996).Applicant
van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (Jul. 1994).Applicant
Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trends Cardiovasc. Med. 3(5):163-170 (1993).Applicant
Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor, Journal of Controlled Release 50:79-92 (1998).Applicant
U.S. Appl. No. 10/376,348, filed Feb. 26, 2003, Ding et al.Applicant